

Global Regulatory Affairs Summit

23-25 October 2018
Hotel Palace Berlin
Berlin, Germany

YOUR ONE STOP SHOP FOR GLOBAL REGULATORY REQUIREMENTS

Whatever your international hurdle, our industry and authority experts have the answers...



lifesciences.knect365.com/global-regulatory-affairs/

#GLOBALRA

KNect365
Life Sciences

DAY ONE: TUESDAY 23 OCTOBER 2018

	Regulatory Affairs in Emerging Markets	Regulatory Affairs in EMEA	Regulatory Data Management and Submissions
08.00	Registration		
	Regulatory Affairs in Russia, Ukraine and the Eurasian Economic Union	European Regulatory Affairs Forum	Regulatory Management
09.00	Chairperson's Opening Remarks	Chairperson's Opening Remarks	Chairperson's Opening Remarks
09.10	CASE STUDY: Successfully undergoing a Russian GMP inspection of manufacturing sites Edelgard Rehak, Dr. Edelgard Rehak Consulting, <i>Russia</i>	Brexit: Implications for Regulatory Affairs professionals and the pharmaceutical industry as a whole Aimad Torqui, Director Global Regulatory Policy, <i>MSD, The Netherlands</i>	Understanding IDMP and SPOR Timelines in the EU and beyond Andrea Herrman, Head of IDMP Office – GRA Operations, <i>Merck</i>
09.45	INTERACTIVE TROUBLESHOOTING SESSION: Practical advice on Russian GMP inspections Alex Dranov, Senior Regulatory & Scientific Affairs Manager, Dr. Willmar Schwabe, GmbH & Co. KG, <i>Germany</i>	The EU Paediatric Regulation: Latest updates including the EU Commission's roadmap for the joint evaluation of the Paediatric and Orphan Regulations Mette Due Theilade Thomsen, Founder, <i>PIP Adviser, Denmark</i>	Debate discussion: To continue with IDMP or not? Jean-Michel Cahen, IDMP Project Lead, <i>Novartis Pharma AG, Switzerland</i>
10.20	The Eurasian Economic Union (EEU) by 2025: Implications for the pharmaceutical industry and practical experiences so far Olga Kravtsova, Head of Regulatory Affairs, <i>BIOCAD, Russia</i>	Orphan medicinal products: Current challenges and opportunities and the latest regulatory landscape David King, Director, Regulatory Policy & Intelligence, <i>Shire, UK</i>	SPOTLIGHT PRESENTATION: Paraxel
10.55	Morning coffee		
11.25	INTERACTIVE DISCUSSION FORUM: Preparing for changes with the new EEU procedures Mariana Novozheniuk, Regulatory Affairs CMC Manager, <i>Bayer AG, Germany</i>	ATMPs in the light of precision (personalised) medicine Hanneke Later-Nijland, Attorney-at-Law Counsel, <i>Axon Lawyers, Law Firm focused on Life Sciences, The Netherlands</i>	Best practices to handle Data migration from XEVMPD to IDMP Laurent Desqueper, XEVMPD & IDMP Business System Owner, <i>MSD Europe Inc (Pending)</i>
12.00	Overview of requirements and practical requirements for creating labels for the EEU Giovanna Ferrari, Regional Labelling Lead, <i>Pfizer, UK</i>	Challenges and opportunities in developing ATmPs such as Allogeneic CAR-T cells Stéphane Reynier, Chief Regulatory and Compliance Officer, <i>Cellceptis, France</i>	PANEL DISCUSSION: Sharing experiences of data migration Patrick Middag, Lead IT Business Partner for Regulatory EU and Data Capabilities, <i>Bristol-Myers Squibb</i>
12.35	Exploring serialisation requirements in Russia and implications for industry Olesya Mertsalova, Regulatory Affairs Cluster Head, <i>EEU, GSK, Russia</i>	EU pharmacovigilance: Updates on the activities of the PRAC Doris Stenver, Chief Medical Officer and Member, Pharmacovigilance Risk Assessment Committee (PRAC), <i>Danish Medicines Agency, Denmark</i>	SPOTLIGHT PRESENTATION/CASE STUDY: Best practices for data mining and converting
13.10	Networking Lunch		

	Regulatory Affairs in Emerging Markets	Regulatory Affairs in EMEA	Regulatory Management
	Regulatory Affairs in Russia, Ukraine and the Eurasian Economic Union	European Regulatory Affairs Forum	Regulatory Management
14.30	CASE STUDY: Best practice for normative document preparation Yuliana Puryшева, Regulatory Affairs Specialist, R-Pharm Group, Russia	The registration dossier: Best practice for European submissions and comparisons to the emerging markets Anna Roznovska, Head of Global Regulatory Affairs, PRO.MED.CS Praha a.s., Czech Republic	Demonstrating a successful RIM system Fidaa F. Odetallah, RIMS Specialist, HIKMA
15.05	Best practices for filing new registrations and CMC variations in Russia Alessandra Leone, Global CMC Sr. Manager, Pfizer, Italy	A patient-centric approach to labelling: Communicating risks to the patient and exploring usability and readability of the SmPC and PIL Patricia Lefebvre, Director Regulatory Labeling, Sanofi-Aventis, France	SPOTLIGHT PRESENTATION: Best practices for data mapping
15.40	Afternoon tea		
16.10	Reviewing the dynamic regulatory environment in Ukraine and practical advice on product registration Anna Altshuler, Head of Regulatory Affairs, Pfizer, Ukraine	CASE STUDY: Exploring codes on packaging, including QR codes and 2d data matrix codes Viktoria Grahnen, Labeling Strategist Manager, Global Labeling, Europe, AbbVie AB, Sweden	Designing an innovative RIM system Laurent Lefebvre, Regulatory CMC Associate Director, Novartis Jean-Michel Cahen, IDMP Project Lead, Novartis Pharma AG, Switzerland
16.45	Examining latest regulatory updates and best strategies for product registration in Ukraine and Moldova Alla Sorokoletova, Director of Medical and Regulatory Affairs Department, PV, QA, Ukraine & CIS, Acino Pharma AG, Ukraine	Exploring the evolution of E-Labeling in Europe: Latest regulatory requirements and expectations Rüdiger Faust, Director, Regulatory Strategy & Intelligence Lead, Grünenthal GmbH, Germany	Ensuring successful RIM system prepared for the Falsified Medicines Directive (FMD)
17.20	Exploring cross-functional leadership for regulatory professionals for market access of pharmaceuticals in emerging markets: Focusing on Ukraine, Russia, Kazakhstan, Belarus, CIS Mariia Govorukha, Manager Regulatory Affairs CIS, Atrium Innovations Inc., Germany	End of Day One	End of Day One
17.55	End of Day One		

DAY TWO: WEDNESDAY 24 OCTOBER 2018

	Regulatory Affairs in Emerging Markets	Regulatory Affairs in EMEA	ESubmissions and IDMP
08.00	Registration		
	Regulatory Affairs in Latin America	European Regulatory Affairs Forum	RIM/Submissions
09.00	Chairperson's Opening Remarks	Chairperson's Opening Remarks	Chairperson's Opening Remarks
09.10	ANVISA: Exploring the latest regulatory updates Leticia Cafruni, Regulatory Affairs Coordinator, AbbVie, Brazil	Comparing regulatory requirements and expectations between Europe and the US Paulina Komorowska, Regulatory Affairs Director EMEA, Valeant Pharma, Poland	Understanding the long term telematic strategy Remco Munnik, Regulatory Information Director, Asphalion S.L., Spain
09.45	CASE STUDY: Practical experience with product registration in Brazil Leticia Cafruni, Regulatory Affairs Coordinator, AbbVie, Brazil	Exploring comparisons between European and US regulatory requirements and expectations Claudia Hey, Senior Director, Head Europe Global Regulatory and Scientific Policy (GRASP), Merck KGaA, Germany, focused on Life Sciences, The Netherlands	(9:55) The impact of SPOR on Regulatory affairs Vada Perkins, Head, Regulatory Intelligence, Bayer
10.20	Examining specific requirements for variations in Brazil Darius-Jean Namdjou, International Regulatory Project Lead, Grünenthal GmbH, Germany	The registration dossier: Best practice for European submissions and comparisons to the emerging markets Anna Roznovska, Head of Global Regulatory Affairs, PRO.MED.CS Praha a.s., Czech Republic	(10:40) Question and Answer Panel on the Telematic Strategy and SPOR Remco Munnik, Regulatory Information Director, Asphalion S.L., Spain Vada Perkins, Head, Regulatory Intelligence, Bayer
10.55	Morning coffee		
11.25	CASE STUDY: Navigating the regulatory environment for product registration in Mexico Stefano Accorsi, Head of Regulatory Affairs "Rest of the World", Chiesi Farmaceutici S.p.A., Italy	SPOTLIGHT PRESENTATION	SPOTLIGHT PRESENTATION: SPOR Taskforce Feedback: Understanding the Substance Management Service
12.00	CASE STUDY: Examining Chile's regulatory environment and successfully registering a product Samuel Bautista, Manager Global Regulatory Affairs, Grünenthal GmbH, Germany	EU pharmacovigilance: Updates on the activities of the PRAC Doris Stenver, Chief Medical Officer and Member, Pharmacovigilance Risk Assessment Committee (PRAC), Danish Medicines Agency, Denmark	FDA feedback on the SRS system and a comparison to SPOR Larry Callahan, Substance Registration System, FDA, USA
12.35	Discussing the regulatory pathways for registration of biologics (Vaccines) in LATAM Arturo Gonzalez-Martinez, Senior Regulatory Expert Japan and LATAM, GSK, Belgium	Case study: Implementing successful global variation strategies Dr. Meike Vanhooren, Senior Director, Pfizer, Germany	Feedback on the implementation of RMS and OMS Dr. Jörg Stüben, Head of Regulatory Information Management and Senior Expert, Boehringer Ingelheim International
13.10	Networking Lunch		

DAY TWO: WEDNESDAY 24 OCTOBER 2018 (continued)

	Regulatory Affairs in Emerging Markets	Regulatory Affairs in EMEA	ESubmissions and IDMP
	Regulatory Affairs in Latin America	European Regulatory Affairs Forum	RIM/Submissions
14.30	CASE STUDY: Sharing best strategies for clinical trial submissions in Latin America Sol Yates, Associate Director, Global Regulatory Affairs, Grünenthal GmbH, <i>Germany</i>	CASE STUDY: Demonstrating an effective grouping strategy for filing variations Anna Krusińska, Regulatory Manager, AbbVie, <i>Poland</i>	Feedback on the Products of SPOR Vada Perkins, Head, Regulatory Intelligence Director, Regulatory Policy & Intelligence, Bayer
15.05	Practically implementing pharmacovigilance and risk management activities in LATAM Cristina de Irala, Pharmacovigilance Consultant, <i>Spain</i>	CASE STUDY: Exploring successful worksharing strategies for filing variations Şebnem Türkes Hartwig, Senior Regulatory Affairs Manager, F. Hoffmann-La Roche Ltd., <i>Switzerland</i>	An introduction to CESSP programme Alastair Nixon, Director Publishing, GlaxoSmithKline (<i>Pending</i>)
15.40	Afternoon tea		
16.10	OPEN FLOOR Q&A DISCUSSION: LATAM Joined by speakers from the day	OPEN FLOOR Q&A DISCUSSION: Europe Tânia Veiga, Regulatory Affairs Europe, Orexigen Therapeutics Ireland Ltd., <i>Ireland</i>	Outlining the status and timelines of ECTD 4.0 Leigh Sandwell, Pfizer
16.45			ELabelling
17.20	End of day two		The future of submission and data management through Automated Intelligence Olga Alfieri, Director, Global Submission Management, Eisai
18.30			End of day two

DAY THREE: THURSDAY 25 OCTOBER 2018

	Regulatory Affairs in Emerging Markets	Regulatory Affairs in EMEA	ESubmissions and IDMP
08.00	Registration		
	Regulatory Affairs in Asia-Pacific	Regulatory Affairs in the Middle East and Africa	Submissions
09.00	Chairperson's Opening Remarks	Chairperson's Opening Remarks	Chairperson's Opening Remarks
09.10	Major regulatory changes China: Staying on top of a turbulent environment Ziqun Han, Director, Zen Medical Science Consultancy, UK	Exploring latest regulatory updates in Oman Dr. Mohammed Hamdan Al Rubaie, Director General of Pharmaceutical Affairs & Drug Control, Ministry of Health, Sultanate of Oman	Overcoming hurdles with submissions in multiple Anna Sahl, Submission Manager, Bayer
09.40	CASE STUDY: Practically complying with the rapidly evolving regulatory landscape in China Ching Li, Manager International, Corporate Regulatory Affairs, Biotest Pharma GmbH, Germany	Regulatory update and practical advice for successful generics' registration in Saudi Arabia Syndie Messager, Market Access and International Regulatory Affairs Coordinator, Laboratorios Cinfa, Spain	Member state feedback from Thai FDA Thai FDA representative, Awaiting final confirmation
10.10	CASE STUDY: Marketing authorizations and latest regulatory updates in India Andrey Mladenov, Senior Manager Regulatory Affairs, Tillotts Pharma AG, Switzerland	Practical advice for product registration and regulatory updates from the Gulf Cooperation Council (GCC) Abdul Mateen, Regulatory Affairs Consultant, AstraZeneca, UK	Experiences in Submitting Dossiers in Thailand Jagraj Sangha, International Regulatory Publishing, Gilead Sciences International Ltd
10.40	Morning coffee		
11.10	Exploring practical considerations for market entry and the latest regulatory environment in South Korea Eric Ducamp, Associate Director, Global Regulatory Affairs, Ipsen, France	Regulatory update and complying with requirements for registration in Iran Abid Hussain, Senior Manager Regulatory Affairs, Emcure Pharmaceuticals Ltd., UAE	Exploring submissions in Brazil A speaker from ANVISA, awaiting confirmation
11.40	Outlining latest regulatory updates in the ASEAN countries and status of the ACTD format Silvia Nita, Global Regulatory Affairs CMC Manager, Roche, Switzerland	Outlining the regulatory environment and practical advice for product registration in Lebanon Ayad Azzi, Regulatory Affairs Manager – Emerging Markets, Boehringer Ingelheim, Germany	Outlining latest regulatory updates in the ASEAN countries and status of the ACTD format Silvia Nita, Global Regulatory Affairs CMC Manager, Roche, Switzerland
12.10	Japan: Examining the latest regulatory environment and practical experiences with MAA submissions Martine Zimmermann, Global Head of Regulatory Affairs, Alexion Pharma GmbH, Switzerland	Exploring regulatory requirements and overcoming challenges across Francophone Africa Marta Abascal, International Market Access & Regulatory Affairs Specialist, Laboratorios Cinfa, Spain	Sharing experiences of successful submissions in GCC Satish Mahajan, Manager, Regulatory Operations – Publishing, GSK
12.40	Networking Lunch		

DAY THREE: THURSDAY 25 OCTOBER 2018 (continued)

	Regulatory Affairs in Emerging Markets	Regulatory Affairs in EMEA	ESubmissions and IDMP
	Regulatory Affairs in Asia-Pacific	Regulatory Affairs in the Middle East and Africa	Submissions
14.00	Understanding orphan drug designation requirements and expectations in Japan Lamine Messaoudi, Co-Founder, RegArise, USA	Understanding the prioritisation of local production in Turkey and implications for industry Figen Kabadas Oge, Head of Regulatory Affairs, Delpharm, France	Roundtables: Question and Answer around the world
14.30	Outlining Australia's latest regulatory requirements for product registration Mahir Karababa, Head Regulatory Affairs RoW, Santhera Pharmaceuticals AG, Switzerland	Latest regulation on the registration of medicinal product and overcoming the challenge of GMP inspections by the Turkish Health Authority Figen Kabadas Oge, Head of Regulatory Affairs, Delpharm, France	CASE STUDY: Preparing for the Mandate of National submissions James Hendry, Head of Global Regulatory Affairs Operations, GE
15.00	Discussing regulatory requirements for labelling and package inserts across APAC Wei Way, Kok, Manager Regulatory Competency Center APAC, Hexal AG/Sandoz, Germany	Practical experiences of labelling in Africa and Middle East – An Overview Ronnie Mundair, Regional Labelling Head- Director, Pfizer, UK	CASE STUDY: Preparing for the Mandate of National submissions Daniel Verrall, Senior Team Manager, Pfizer
15:30	Afternoon tea		
16.00	OPEN FLOOR Q&A DISCUSSION: APAC Ching Li, Manager International, Corporate Regulatory Affairs, Biotest Pharma GmbH, Germany Ziqun Han, Director, Zen Medical Science Consultancy, UK Justyna Kwiatkowska, Junior Regulatory Affairs Specialist, Adamed Group, Poland	Latest regulatory updates and best practice for biosimilars registration in Turkey and MENA Parminder Kaur, Founder and RA/PV Consultant, RegPak BioPharma Consulting, The Netherlands	Ensuring industry are prepared for Policy 0070 A representative from PPP Solutions
16.30	Alan Chalmers, Director, Pharma International, Switzerland	Exploring latest status and updates of 'fast track' approvals and priority reviews conducted in Turkey and MENA Edmar Campos, Intercontinental Coordinator, Global Regulatory Affairs, Ipsen, France	Defining the right level of RA technical checks of regulatory files Carolline Petersen, Project Manager, Novo Nordisk
17.00	End of day three	OPEN FLOOR Q&A DISCUSSION: Middle East and Africa Dr Salah Chettibi, Regulatory Affairs Manager, Kyowa Kirin Services Ltd, UK	End of day three
18:00		End of day three	

PROMOTE NEW AND EXISTING PRODUCTS AND SERVICES TO OUR HIGH LEVEL DELEGATION

We can provide flexible and tailored solutions to optimise your investment. Below are some examples of how you can get involved at the event.

Speaking Opportunities

- Demonstrate your thought leadership to the most senior level audience. Raise your profile, share your experiences and position yourself as one of the go-to companies in your business area.
- Deliver a keynote address or presentation
- Participate in a high level panel discussion and interact with the audience
- Moderate or present during a breakout session

Branding Packages

- Create greater awareness of your brand and ensure your company stands out in the crowd. Branding sponsorship options include:
- Conference Bag Sponsor
- Delegate Badge/Lanyard Sponsor
- Wifi Sponsor
- Registration Sponsor
- Mobile App Sponsor

Hospitality Packages

- Ensure your company or product is the talk of the conference by hosting social functions including drinks receptions, lunch breaks, coffee breaks, a networking dinner, evening entertainment, and more
- Networking Drinks Sponsor
- Networking Lunch Sponsor
- Coffee Break Sponsor

Exhibition Packages

- Join the exhibition where all refreshments and lunch is served. This offers extensive networking and helps delegates and speakers to connect with relevant suppliers. Showcase your expertise, build new contacts and demonstrate your products and services.
- Sponsorship and exhibition opportunities are limited - book now to avoid disappointment. Email Alexander Zenonos to find out more - Alexander.zenonos2@informa.com or call +44 (0) 20 7017 7742

1 to 1 Meetings & Networking

With access to 200+ industry professionals the event provides the ultimate opportunity to meet current and prospective clients. Use the event networking app to arrange 1 to 1 meetings with key decision makers ahead of the event to optimise your time on site.



To learn more about available sponsorship & exhibition opportunities, contact Roger Challinor: T: Roger.Challinor@KNect365.com | +44 (0) 20 7017 7387

For speaking opportunities, contact Rebecca Brady: Rebecca.Brady@KNect365.com | +44 (20) 701 77546